CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / ELI Lilly & CO (LLY) / orforglipron
Forward catalyst · LLY

orforglipron

Sponsor ELI Lilly & CO · listed as LLY

READOUT Phase 3 Confidence: medium Source: clinicaltrials

orforglipron is a drug asset sponsored by ELI Lilly & CO, listed as LLY. CSA tracks 5 forward catalysts for it — the nearest is a readout expected Feb 2027 (month precision, medium confidence), tied to trial NCT06672549. That trial is in Phase 3 and currently recruiting, studying Obesity. It appears across 17 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-02-28
As disclosedFeb 2027
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06672549
PhasePHASE3
StatusRECRUITING
Lead sponsorEli Lilly and Company
Listed asLLY
Condition(s)Obesity; Overweight

Other tracked assets in the same trials — NCT07668336: dulaglutide.

All tracked catalysts for orforglipron

DateEventConfidenceTrial
2027-02-28READOUTmediumNCT06672549
2027-05-31READOUTmediumNCT07613307
2027-08-31READOUTmediumNCT06972459
2027-09-30READOUTmediumNCT06948422
2027-12-31READOUTmediumNCT06672939

Trials for orforglipron in the CSA sample

TrialPhaseStatusPrimary completionRoleLead sponsorCondition(s)
NCT05869903Phase 3Active, not recruiting2025-07-25ExperimentalEli Lilly and CompanyObesity; Overweight; Overweight or Obesity
NCT06672549 catalystPhase 3Recruiting2027-02ExperimentalEli Lilly and CompanyObesity; Overweight
NCT07613307 catalystPhase 3Recruiting2027-05ExperimentalEli Lilly and CompanyDiabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Diso…
NCT06972459 catalystPhase 3Active, not recruiting2027-08ExperimentalEli Lilly and CompanyObesity; Overweight
NCT06972472Phase 3Active, not recruiting2027-08ExperimentalEli Lilly and CompanyObesity; Overweight; Type 2 Diabetes
NCT06993792Phase 3Active, not recruiting2027-08ExperimentalEli Lilly and CompanyObesity; Overweight; Type 2 Diabetes
NCT06948422 catalystPhase 3Active, not recruiting2027-09ExperimentalEli Lilly and CompanyHypertension
NCT06948435Phase 3Active, not recruiting2027-09ExperimentalEli Lilly and CompanyHypertension; Overweight or Obesity
NCT06952530Phase 3Active, not recruiting2027-09ExperimentalEli Lilly and CompanyHypertension
NCT06672939 catalystPhase 3Recruiting2027-12ExperimentalEli Lilly and CompanyObesity; Overweight
NCT07202884Phase 3Recruiting2028-03ExperimentalEli Lilly and CompanyUrinary Incontinence,Stress
NCT07790861Phase 3Not yet recruiting2028-03ExperimentalEli Lilly and CompanyObesity; Overweight
NCT07153471Phase 3Active, not recruiting2028-04ExperimentalEli Lilly and CompanyOsteoarthritis
NCT07223593Phase 3Recruiting2028-06ExperimentalEli Lilly and CompanyPeripheral Arterial Disease
NCT07794579Phase 3Recruiting2029-08ExperimentalEli Lilly and CompanyOverweight; Prediabetic State; Prehypertension; Obesity, Abdominal
NCT07668336Phase 3Not yet recruiting2030-03ExperimentalEli Lilly and CompanyDiabetes Mellitus, Type 2
NCT07241390Phase 3Recruiting2031-08ExperimentalEli Lilly and CompanyAtherosclerosis Cardiovascular Disease; Chronic Kidney Disease

Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.

!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.

Get the full dataset — $499 →   More LLY catalysts

Related catalysts and sponsor